An update from the ongoing Phase 1/2 Alta trial supports that a single infusion of SB-525 leads to stable and relevant improvements in clotting factor VIII.
An update from the ongoing Phase 1/2 Alta trial supports that a single infusion of SB-525 leads to stable and relevant improvements in clotting factor VIII.
No comments:
Post a Comment